Us Bancorp \De\ Tcr2 Therapeutics Inc. Transaction History

Us Bancorp \De\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$2.4 - $4.71 $360 - $706	-150 Reduced 17.65%	700 $2,000
Q4 2021 Feb 11, 2022	SELL	$4.58 - $8.34 $16,744 - $30,491	-3,656 Reduced 81.14%	850 $4,000
Q3 2021 Nov 10, 2021	SELL	$8.44 - $18.35 $155,025 - $337,052	-18,368 Reduced 80.3%	4,506 $38,000
Q2 2021 Aug 05, 2021	BUY	$16.41 - $24.71 $2,461 - $3,706	150 Added 0.66%	22,874 $375,000
Q1 2021 Apr 28, 2021	BUY	$20.38 - $34.07 $26,677 - $44,597	1,309 Added 6.11%	22,724 $502,000
Q4 2020 Feb 04, 2021	BUY	$19.0 - $32.63 $393,585 - $675,930	20,715 Added 2959.29%	21,415 $663,000
Q1 2020 May 13, 2020	BUY	$6.01 - $16.01 $1,803 - $4,803	300 Added 75.0%	700 $5,000
Q3 2019 Nov 08, 2019	BUY	$10.15 - $19.53 $4,060 - $7,812	400 New	400 $6,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.